{"id":"NCT00420199","sponsor":"Bristol-Myers Squibb","briefTitle":"A Phase IIIb Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate","officialTitle":"A Phase IIIB Multicenter, Randomized, Double-Blind, Placebo-controlled Study to Assess Short-term Changes in Synovitis and Structural Damage Outcomes in Subjects With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate, Treated With Abatacept Versus Placebo on a Background Therapy With Methotrexate","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-05","primaryCompletion":"2009-08","completion":"2010-05","firstPosted":"2007-01-09","resultsPosted":"2011-05-17","lastUpdate":"2012-01-18"},"enrollment":50,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Active Rheumatoid Arthritis"],"interventions":[{"type":"DRUG","name":"Abatacept","otherNames":["(BMS-188667)","Orencia"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Abatacept + Methotrexate (Double-blind period)","type":"ACTIVE_COMPARATOR"},{"label":"Placebo + Methotrexate (Double-blind period)","type":"PLACEBO_COMPARATOR"}],"summary":"The only trial in participants who are methotrexate-inadequate responders and have active Rheumatoid Arthritis, in which gadolinium-enhanced Magnetic Resonance Imaging; Bone Mineral Density; and biochemical markers of bone, cartilage, and synovial tissue metabolism are used to evaluate early effects (4 months) of Abatacept on inflammation/structural damage. Study will provide valuable mechanism-of-action information on how Abatacept exerts its effects (including on bone) through new techniques.","primaryOutcome":{"measure":"Double-blind Period: Mean Synovitis Scores at Baseline As Measured by the Rheumatoid Arthritis Clinical Trials 6 (OMERACT 6) Rheumatoid Arthritis Magnetic Resonance Imaging Score (RAMRIS)","timeFrame":"At baseline","effectByArm":[{"arm":"Abatacept + Methotrexate","deltaMin":4.48,"sd":2.1},{"arm":"Placebo + Methotrexate","deltaMin":3.52,"sd":2.43}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":null},"locations":{"siteCount":10,"countries":["Belgium","Germany","Netherlands","Spain","Sweden","United Kingdom"]},"refs":{"pmids":["22915624"],"seeAlso":["http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":27},"commonTop":["NAUSEA","HEADACHE","DIARRHOEA","NASOPHARYNGITIS","BACK PAIN"]}}